Log In Get Started
Insider Trading June 23, 2026 09:41 PM

Spyre Therapeutics Director Henderson Offloads $2 Million in Equity Under Pre-Arranged Plan

Insider sale occurs as the biotech firm navigates a period of clinical milestones and elevated valuation metrics.

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
SYRE

Michael Thomas Henderson, a member of the board at Spyre Therapeutics Inc. (NASDAQ: SYRE), executed a transaction to sell 20,000 shares of the company's common equity on June 22, 2026. The disposition of these shares resulted in a gross transaction value of $2,000,000, with each share priced at $100. This activity follows a period of significant price appreciation for SYRE, which has traded near its 52-week high of $102.06 after posting a 530% return over the trailing twelve months. Concurrently, the company has reported clinical progress and completed a substantial capital raise, alongside revised analyst price targets.

Spyre Therapeutics Director Henderson Offloads $2 Million in Equity Under Pre-Arranged Plan
SYRE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Michael Thomas Henderson, a director at Spyre Therapeutics (NASDAQ: SYRE), sold 20,000 shares on June 22, 2026, at $100 per share, totaling $2,000,000. The transaction was executed under a Rule 10b5-1 plan established on February 6, 2026. Following the sale, Henderson retains direct ownership of 68,606 shares.
  • Spyre Therapeutics has experienced a 530% return over the past year, with shares trading near a 52-week high of $102.06. InvestingPro analysis suggests the stock may be overvalued at current levels based on Fair Value calculations. The company also closed a $463.5 million stock offering, selling over 7 million shares at $62.00 each.
  • The biotech firm reported positive phase 2 results for SPY002 in ulcerative colitis and completed enrollment for the SKYWAY basket trial targeting rheumatic diseases. Deutsche Bank raised its price target to $115 due to a competitor's setback, while Stifel increased its target to $107 citing strong data for SPY001.

Michael Thomas Henderson, serving in a director capacity at Spyre Therapeutics Inc. (NASDAQ: SYRE), completed a sale of 20,000 shares of the company's common stock on June 22, 2026. The transaction, valued at $2,000,000 in total, was executed at a price of $100 per share. Following the completion of this sale, Henderson maintains a direct holding of 68,606 shares of SYRE common stock.

The disposition was carried out under the parameters of a Rule 10b5-1 trading plan, which was initially established on February 6, 2026. This sale activity coincides with a period of substantial market performance for Spyre Therapeutics. The stock has been trading in close proximity to its 52-week high of $102.06. This current price level reflects a remarkable 530% return over the past year.

According to analysis provided by InvestingPro, the current valuation of SYRE may be considered overvalued based on specific Fair Value calculations. The platform highlights detailed metrics and offers 15 additional ProTips for investors conducting due diligence on the stock.

In parallel with the insider transaction, Spyre Therapeutics has announced positive clinical outcomes from its phase 2 trial for SPY002, a therapeutic candidate targeting ulcerative colitis. The trial, identified as SKYLINE, recorded a significant reduction in Robart's Histopathology Index score. This result marks a notable development for the company's pipeline.

Furthermore, Spyre has finalized enrollment for its SKYWAY basket trial. This study investigates SPY072 across various rheumatic diseases, with data readouts anticipated by late 2026. On the capital markets front, the company successfully closed a $463.5 million stock offering. This transaction involved the sale of over 7 million shares at a price of $62.00 each.

Analyst sentiment has also seen adjustments. Deutsche Bank has raised its price target for Spyre to $115. The firm attributes this increase to a setback experienced by a competitor. Similarly, Stifel has increased its price target to $107. Stifel cites strong data for another ulcerative colitis treatment, SPY001, as the primary driver for this revision. These developments suggest Spyre is actively positioning itself within the pharmaceutical sector.

Risks

  • The stock has appreciated 530% over the past year, and InvestingPro analysis indicates it may be overvalued based on Fair Value calculations, suggesting potential downside risk if valuation multiples contract.
  • The company recently completed a $463.5 million stock offering, selling over 7 million shares at $62.00 each, which may introduce dilution to existing shareholders.
  • Clinical trial outcomes for SPY002 and SPY072 remain subject to regulatory and development risks, with SKYWAY data expected only by late 2026, leaving a period of uncertainty for investors.

More from Insider Trading

ConnectM CFO Choudhury Accumulates Shares Ahead of Sharp Price Rally Jun 23, 2026 ConnectM CEO Increases Holdings Amid Market Volatility Jun 23, 2026 Spyre Therapeutics Director-Affiliated Fund Liquidates Nearly $400 Million Stake Jun 23, 2026 Crescent Biopharma CFO Sells Shares to Cover Tax Obligations Amid Clinical Developments Jun 23, 2026 Crescent Biopharma Director Disposes of RSU-Linked Shares via Rule 10b5-1 Plan Jun 23, 2026